Inhibition of metalloproteinases derived from tumours: New insights in the treatment of human glioblastoma

Neuroscience

Volumn 168, Issue 2, 2010, Pages 514-522

  Gabelloni, P ^a   Da Pozzo, E ^a   Bendinelli, S ^a   Costa, B ^a   Nuti, E ^a   Casalini, F ^a   Orlandini, E ^a   Da Settimo, F ^a   Rossello, A ^a   Martini, C ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Glioma; Invasiveness; Metalloproteinase inhibitor; Multitarget therapy; Temozolomide

Indexed keywords

CGS 27023A; GELATINASE A; GELATINASE B; HYDROXAMIC ACID DERIVATIVE; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE 14; STROMELYSIN; TEMOZOLOMIDE;

ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG STRUCTURE; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHEMOTAXIS; DACARBAZINE; DRUG INTERACTIONS; GLIOBLASTOMA; HUMANS; HYDROXAMIC ACIDS; MATRIX METALLOPROTEINASE 2; NEOPLASM INVASIVENESS; SULFONAMIDES;

EID: 77952880523     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.03.064     Document Type: Article

References (42)

1. Albini A., Benelli R. The chemoinvasion assay: a method to assess tumor and endothelial cell invasion and its modulation. Nat Protoc 2007, 2:504-511.
2. Brada M., Judson I., Beale P., Moore S., Reidenberg P., Statkevich P., Dugan M., Batra V., Cutler D. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 1999, 81:1022-1030.
3. Brown P.D., Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Oncol 1995, 6:967-974.
4. Cauwe B., Van den Steen P.E., Opdenakker G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol 2007, 42:113-185.
5. Chelli B., Lena A., Vanacore R., Da Pozzo E., Costa B., Rossi L., Salvetti A., Scatena F., Ceruti S., Abbracchio M.P., Gremigni V., Martini C. Peripheral benzodiazepine receptor ligands: mitochondrial transmembrane potential depolarization and apoptosis induction in rat C6 glioma cells. Biochem Pharmacol 2004, 68:125-134.
6. Conrad C.A., Milosavljevic V.P., Yung W.K. Advances in chemotherapy for brain tumors. Neurol Clin 1995, 13:795-812.
7. Dehdashti A.R., Hegi M.E., Regli L., Pica A., Stupp R. New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy. Neurosurg Focus 2006, 20:E6.
8. Desjardins A., Rich J.N., Quinn J.A., Vredenburgh J., Gururangan S., Sathornsumetee S., Reardon D.A., Friedman A.H., Bigner D.D., Friedman H.S. Chemotherapy and novel therapeutic approaches in malignant glioma. Front Biosci 2005, 10:2645-2668.
9. Forsyth P.A., Wong H., Laing T.D., Rewcastle N.B., Morris D.G., Muzik H., Leco K.J., Johnston R.N., Brasher P.M., Sutherland G., Edwards D.R. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer 1999, 79:1828-1835.
10. Giese A., Bjerkvig R., Berens M.E., Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003, 21:1624-1636.
11. Groves M.D., Puduvalli V.K., Hess K.R., Jaeckle K.A., Peterson P., Yung W.K., Levin V.A. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 2002, 20:1383-1388.
12. Heino J. Biology of tumor cell invasion: interplay of cell adhesion and matrix degradation. Int J Cancer 1996, 65:717-722.
13. Hess K.R., Broglio K.R., Bondy M.L. Adult glioma incidence trends in the United States, 1977-2000. Cancer 2004, 101:2293-2299.
14. Hirose Y., Berger M.S., Pieper R.O. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 2001, 61:1957-1963.
15. Johannesen T.B., Angell-Andersen E., Tretli S., Langmark F., Lote K. Trends in incidence of brain and central nervous system tumors in Norway, 1970-1999. Neuroepidemiology 2004, 23:101-109.
16. Kachra Z., Beaulieu E., Delbecchi L., Mousseau N., Berthelet F., Moumdjian R., Del Maestro R., B'eliveau R. Expression of matrix metalloproteinases and their inhibitors in human brain tumors. Clin Exp Metastasis 1999, 17:555-566.
17. Kawasaki Y., Xu Z.Z., Wang X., Park J.Y., Zhuang Z.Y., Tan P.H., Gao Y.J., Roy K., Corfas G., Lo E.H., Ji R.R. Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nat Med 2008, 14:331-336.
18. Kerkvliet E.H., Jansen I.D., Schoenmaker T.A., Docherty A.J., Beertsen W., Everts V. Low molecular weight inhibitors of matrix metalloproteinases can enhance the expression of matrix metalloproteinase-2 (gelatinase A) without inhibiting its activation. Cancer 2003, 97:1582-1588.
19. Kim S.Y., Lee E.J., Woo M.S., Jung J.S., Hyun J.W., Min S.W., Kim D.H., Kim H.S. Inhibition of matrix metalloproteinase-9 gene expression by an isoflavone metabolite, irisolidone in U87MG human astroglioma cells. Biochem Biophys Res Commun 2008, 366:493-499.
20. Knight C.G., Willenbrock F., Murphy G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett 1992, 296:263-266.
21. Konstantinopoulos P.A., Karamouzis M.V., Papatsoris A.G., Papavassiliou A.G. Matrix metalloproteinase inhibitors as anticancer agents. Int J Biochem Cell Biol 2008, 40:1156-1168.
22. Lee S.K., Chun H.K., Yang J.Y., Han D.C., Son K.H., Kwon B.M. Inhibitory effect of obovatal on the migration and invasion of HT1080 cells via the inhibition of MMP-2. Bioorg Med Chem 2007, 15:4085-4090.
23. Lein M., Jung K., Le D.K., Hasan T., Ortel B., Borchert D., Winkelmann B., Schnorr D., Loenings S.A. Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model. Prostate 2000, 43:77-82.
24. Levin V.A., Leibel S.A., Gutin P.H. Neoplasms of the central nervous system. Cancer: principles of oncology 2001, 2100-2161. Lippincott-Raven, Philadelphia, PA. V.T. De Vita, S. Hellman, S.A. Rosenberg (Eds.).
25. Levin V.A., Phuphanich S., Yung W.K., Forsyth P.A., Maestro R.D., Perry J.R., Fuller G.N., Baillet M. Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J Neuro Oncol 2006, 78:295-302.
26. Lim S.H., Jeong Y.I., Moon K.S., Ryu H.H., Jin Y.H., Jin S.G., Jung T.Y., Kim I.Y., Kang S.S., Jung S. Anticancer activity of PEGylated matrix metalloproteinase cleavable peptide conjugated adriamycin against malignant glioma cells. Int J Pharm 2009, 387:209-214.
27. MacPherson L.J., Bayburt E.K., Capparelli M.P., Carroll B.J., Goldstein R., Justice M.R., Zhu L.J., Hu S.I., Melton R.A., Fryer L., Goldberg R.L., Doughty J.R., Spirito S., Blancuzzi V., Wilson D., O'Byrne E.M., Ganu V., Parker D.T. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J Med Chem 1997, 40:2525-2532.
28. Nagase H., Woessner J.F. Matrix metalloproteinases. J Biol Chem 1999, 274:21491-21494.
29. Nuti E., Casalini F., Avramova S.I., Santamaria S., Cercignani G., Marinelli L., La Pietra V., Novellino E., Orlandini E., Nencetti S., Tuccinardi T., Martinelli A., Lim N.H., Visse R., Nagase H., Rossello A. N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis. J Med Chem 2009, 52:4757-4773.
30. Papi A., Bartolini G., Ammar K., Guerra F., Ferreri A.M., Rocchi P., Orlandi M. Inhibitory effects of retinoic acid and IIF on growth, migration and invasiveness in the U87MG human glioblastoma cell line. Oncol Rep 2007, 18:1015-1021.
31. Plate K.H., Breier G., Weich H.A., Mennel H.D., Risau W. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 1994, 59:520-529.
32. Rabbani S.A., Harakidas P., Guo Y., Steinman D., Davidsen S.K., Morgan D.W. Synthetic inhibitor of matrix metalloproteases decreases tumor growth and metastases in a syngeneic model of rat prostate cancer in vivo. Int J Cancer 2000, 87:276-282.
33. Rossello A., Nuti E., Orlandini E., Carelli P., Rapposelli S., Macchia M., Minutolo F., Carbonaro L., Albini A., Benelli R., Cercignani G., Murphy G., Balsamo A. New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2). Bioorg Med Chem 2004, 12:2441-2450.
34. Rossello A., Nuti E., Carelli P., Orlandini E., Macchia M., Nencetti S., Zandomeneghi M., Balzano F., Uccello Barretta G., Albini A., Benelli R., Cercignani G., Murphy G., Balsamo A. N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP. Bioorg Med Chem Lett 2005, 15:1321-1326.
35. Ruan S., Okcu M.F., Pong R.C., Andreeff M., Levin V., Hsieh J.T., Zhang W. Attenuation of WAF1/Cip1 expression by an antisense adenovirus expression vector sensitizes glioblastoma cells to apoptosis induced by chemotherapeutic agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin. Clin Cancer Res 1999, 5:197-202.
36. Sarkar S., Nuttall R.K., Liu S., Edwards D.R., Yong V.W. Tenascin-C stimulates glioma cell invasion through matrix metalloproteinase-12. Cancer Res 2006, 66:11771-11780.
37. Tonn J.C., Kerkau S., Hanke A., Bouterfa H., Mueller J.G., Wagner S., Vince G.H., Roosen K. Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro. Int J Cancer 1999, 80:764-772.
38. Vihinen P., Kähäri V.M. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002, 99:157-166.
39. Virrey J.J., Golden E.B., Sivakumar W., Wang W., Pen L., Schönthal A.H., Hofman F.M., Chen T.C. Glioma-associated endothelial cells are chemoresistant to temozolomide. J Neuro Oncol 2009, 95:13-22.
40. Wang M., Wang T., Liu S., Yoshida D., Teramoto A. The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades. Brain Tumor Pathol 2003, 20:65-72.
41. Wang M., Yoshida D., Liu S., Teramoto A. Inhibition of cell invasion by indomethacin on glioma cell lines: in vitro study. J Neuro Oncol 2005, 72:1-9.
42. Whittaker M., Floyd C.D., Brown P., Gearing A.J. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev 1999, 99:2735-2776.